Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
Marzec, Michal; Zhang, Qian; Goradia, Ami; Raghunath, Puthiyaveettil N; Liu, Xiaobin; Paessler, Michele; Wang, Hong Yi; Wysocka, Maria; Cheng, Mangeng; Ruggeri, Bruce A; Wasik, Mariusz A.
Proc Natl Acad Sci U S A
; 105(52): 20852-7, 2008 Dec 30.
Artigo em Inglês | MEDLINE | ID: mdl-19088198
ROS1 fusions in cancer: a review.
Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.
Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing.
Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer.
Structural basis for the recognition of c-Src by its inactivator Csk.
The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.
Molecular pathways: ROS1 fusion proteins in cancer.